Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.

Abstract

Ceftobiprole is a novel broad-spectrum cephalosporin that binds with high affinity to PBP 2a, the methicillin-resistance determinant of staphylococci, and is active against methicillin- and vancomycin-resistant Staphylococcus aureus. Ceftobiprole was compared to vancomycin in a rabbit model of methicillin-resistant S. aureus aortic valve endocarditis. Ceftobiprole and vancomycin were equally effective against endocarditis caused by methicillin-resistant S. aureus strain 76, whereas ceftobiprole was more effective than vancomycin against the vancomycin-intermediate S. aureus strain HIP5836. The activity of ceftobiprole against drug-resistant strains of S. aureus warrants its further clinical development.

• Authors: Henry F Chambers
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 49 Issue 3 Pg. 884-8 (Mar 2005) ISSN: 0066-4804 [Print] United States
• PMID: 15728879 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cephalosporins
• ceftobiprole
• Vancomycin

Topics

• Animals
• Aortic Valve
• Cephalosporins (blood, therapeutic use)
• Disease Models, Animal
• Endocarditis, Bacterial (drug therapy)
• Heart Valve Diseases (drug therapy)
• Methicillin Resistance
• Microbial Sensitivity Tests
• Rabbits
• Staphylococcal Infections (drug therapy)
• Staphylococcus aureus (drug effects)
• Vancomycin (blood, therapeutic use)